Chanca Piedra Active Compounds: Lignans, Ellagitannins, and the Bioavailability Story

Table of Contents

1. Lignans: Phyllanthin, Hypophyllanthin, Niranthin, Nirtetralin
2. Ellagitannins: Geraniin, Corilagin, Ellagic Acid
3. Flavonoids: Rutin, Quercetin, Niruretin
4. Compound → Effect Mapping
5. Bioavailability and Microbiota Activation
6. CYP450 and P-Glycoprotein Effects
7. Standardization Markers in Practice
8. Species Chemotypes
9. Whole Herb vs Isolated Extract
10. Key Research Papers
11. Connections
12. Featured Videos

Lignans: Phyllanthin, Hypophyllanthin, Niranthin, Nirtetralin

The aryltetralin lignans are the most-cited class of Chanca Piedra actives, concentrated mostly in the leaves.

• Phyllanthin — the lead marker compound for standardization; hepatoprotective via membrane stabilization and tumor necrosis factor-alpha suppression; mechanism-based inhibitor of cytochrome P450 3A4 (CYP3A4); direct P-glycoprotein inhibitor in Caco-2 cells (effect lost on washout, suggesting reversible binding); highly permeable (transcellular passive diffusion); plasma-detectable for >10 hours after oral dosing in rats.
• Hypophyllanthin — companion to phyllanthin; similar pharmacology with overlapping hepatoprotection; recent evidence of distinct contributions to anti-inflammatory pathways.
• Niranthin — the principal driver of hepatitis B virus (HBV) polymerase / reverse-transcriptase inhibition; also contributes to the uricosuric effect.
• Nirtetralin — supports the antiviral profile; less studied than the other three.

Lignan concentrations vary by species: P. amarus typically has the highest combined phyllanthin + hypophyllanthin + niranthin content, which is part of why it dominates the hepatitis B trial literature.

Ellagitannins: Geraniin, Corilagin, Ellagic Acid

The ellagitannins are large polyphenols that drive most of the antioxidant and anti-crystallization activity.

• Geraniin — the signature ellagitannin, approximately 1–4% dry weight in P. urinaria. Antioxidant powerhouse via its hexahydroxydiphenoyl (HHDP) and dehydrohexahydroxydiphenoyl (DHHDP) groups. Native bioavailability is poor (too polar/large to cross enterocytes); active forms are gut metabolites — geraniin hydrolyzes in the gastrointestinal (GI) tract to corilagin, ellagic acid, brevifolin, and gallic acid, which are then further converted to urolithins by intestinal bacteria. Antiviral, anti-inflammatory.
• Corilagin — a primary geraniin breakdown product. Anti-inflammatory via NF-kappaB suppression; antiviral; inhibits calcium oxalate crystal aggregation — likely the primary kidney-stone effect driver alongside geraniin itself. Also anti-fibrotic in liver models.
• Ellagic acid and ellagitannins — antioxidant, anti-mutagenic. Like geraniin, much of the bioactivity is from microbiota-derived urolithins (urolithin A and B), not the parent compounds.

Flavonoids: Rutin, Quercetin, Niruretin

Secondary contributors to the overall pharmacology:

• Rutin — glycosylated quercetin; mild xanthine oxidase inhibition; capillary support and anti-edema effects.
• Quercetin glycosides — antioxidant, mast-cell stabilization, antihistamine activity.
• Niruretin — a Chanca Piedra-specific flavonoid; antioxidant; modest contribution to glucose-lowering via alpha-glucosidase inhibition and AMP-activated protein kinase (AMPK) activation.

Compound → Effect Mapping

Which compound drives which effect:

• Kidney stones — corilagin + geraniin (crystal-aggregation inhibition); triterpenes (antilithogenic); lignans add a uricosuric push (urinary uric-acid clearance up to 11-fold in animal models)
• Hepatitis B — niranthin, nirtetralin, phyllanthin (hepatitis B virus polymerase / reverse-transcriptase inhibition)
• Liver protection (non-viral) — phyllanthin + hypophyllanthin (membrane stabilization, antioxidant)
• Xanthine oxidase inhibition / uric acid — flavonoids (rutin, quercetin glycosides) drive XO inhibition; lignans add uricosuric effect
• Glucose lowering — flavonoids + corilagin (insulin-sensitizing); flavonoids drive alpha-glucosidase inhibition
• Hypertension / ACE-like activity — geraniin + corilagin via tannin-zinc chelation at the ACE active site
• Antioxidant capacity — geraniin and downstream urolithin metabolites; flavonoids contribute

Bioavailability and Microbiota Activation

Phyllanthus pharmacokinetics are a study in why "what's in the supplement bottle" doesn't equal "what reaches your bloodstream":

• Phyllanthin and hypophyllanthin cross intestinal cell layers readily by passive diffusion in Caco-2 cell tests, but phyllanthin's very low water solubility limits absorption; in a rat study, oral absorption was incomplete, with absolute oral bioavailability of 0.62% for phyllanthin and 1.52% for hypophyllanthin. They reach plasma but undergo extensive Phase I metabolism. Half-life is several hours in rats; human PK data are limited.
• Geraniin is too polar and large to cross enterocytes intact — native bioavailability is essentially zero. The active forms are downstream metabolites, produced by:
  1. Hydrolysis in stomach acid → corilagin + ellagic acid
  2. Further hydrolysis → brevifolin, gallic acid, smaller phenolics
  3. Intestinal microbiota conversion of ellagic acid → urolithin A and urolithin B (the actually-absorbed bioactive forms)
• Urolithin A in particular has its own developing research base for mitochondrial health, anti-inflammatory effects, and longevity. Chanca Piedra is one dietary source; pomegranate and walnuts are others.

This pathway has two important consequences. First, gut microbiota composition matters — not everyone produces urolithins efficiently, which may explain some inter-individual variability in response. Second, isolated geraniin or corilagin extracts are not the same as whole-herb preparations, because the gut conversion is part of the therapeutic activation.

CYP450 and P-Glycoprotein Effects

Phyllanthus modulates several drug-metabolizing systems in ways that matter clinically:

• Cytochrome P450 3A4 (mechanism-based inhibition) — phyllanthin and hypophyllanthin bind cytochrome P450 3A4 in a way that produces irreversible enzyme suicide; effect persists until new enzyme is synthesized (hours to days). This is the most clinically important interaction pathway.
• CYP2C9 — inhibition; relevant for warfarin, nonsteroidal anti-inflammatory drugs (NSAIDs), certain anticonvulsants
• CYP1A2, CYP2D6, CYP2E1 — lesser inhibition, but documented
• P-glycoprotein — phyllanthin and hypophyllanthin are direct P-gp inhibitors in Caco-2 cells (no MRP2 effect). P-gp inhibition raises plasma levels of P-gp-substrate drugs (digoxin, certain calcium-channel blockers, some antiretrovirals)

For the practical drug-interaction list, see Safety & Drug Interactions.

Standardization Markers in Practice

Reputable extracts are typically standardized to:

• 3–5% phyllanthin — most common
• "Total lignans 5%" (phyllanthin + hypophyllanthin combined) — alternative
• 10:1 full-spectrum extract — concentration ratio rather than marker compound

What's missing from most labels: ellagitannin / geraniin content. This is a meaningful gap because corilagin and geraniin drive much of the kidney-stone activity. Look for HPLC-verified phyllanthin ≥3% AND a stated tannin or geraniin specification when possible. Most products don't provide it; the buyer is left trusting that whole-herb sourcing has captured the tannin fraction along with the lignans.

Species Chemotypes

• P. amarus — highest phyllanthin, hypophyllanthin, niranthin (best for hepatoprotection / hepatitis B virus claims)
• P. niruri (true) — high hypophyllanthin and phenolics
• P. urinaria — highest geraniin and corilagin; richer ellagitannin profile (best for stone prevention and antioxidant claims). One recent study suggests P. urinaria may also have the highest phyllanthin content, contradicting older literature

These are commonly conflated on commercial labels — "Chanca Piedra" can be any of the three, often without clear identification. See Phyllanthus Species Comparison.

Whole Herb vs Isolated Extract

For Chanca Piedra, the whole-herb argument is more than marketing rhetoric:

• The native geraniin → microbiota → urolithin cascade is the entire bioavailability pathway. Bypassing the intact ellagitannins (with isolated phyllanthin only) loses this
• Phyllanthin and hypophyllanthin act synergistically, not additively, in some pharmacological assays (e.g., doxorubicin re-sensitization studies)
• Corilagin's anti-fibrotic activity complements phyllanthin's hepatoprotection
• The flavonoid contribution to xanthine oxidase inhibition is lost in lignan-only extracts

For most clinical uses, a standardized whole-herb extract (3–5% phyllanthin from a quality-tested source) is the right balance of consistency and full pharmacology. Isolated phyllanthin or isolated geraniin products are research tools, not therapeutic forms.

Back to Table of Contents

Key Research Papers

1. Taesotikul T, Dumrongsakulchai W, Wattanachai N, et al. (2011). Inhibitory effects of Phyllanthus amarus and its major lignans on human microsomal cytochrome P450 activities: evidence for CYP3A4 mechanism-based inhibition. Drug Metabolism and Pharmacokinetics — PubMed PMID: 21178301
2. Sukhaphirom N, Vardhanabhuti N, Chirdchupunseree H, et al. (2013). Phyllanthin and hypophyllanthin inhibit function of P-gp but not MRP2 in Caco-2 cells. The Journal of Pharmacy and Pharmacology — PubMed PMID: 23278697
3. Dunkoksung W, Vardhanabhuti N, Jianmongkol S (2019). Potential P-glycoprotein-mediated herb-drug interaction of phyllanthin at the intestinal absorptive barrier. The Journal of Pharmacy and Pharmacology — PubMed PMID: 30251430
4. Murugaiyah V, Chan KL (2007). Analysis of lignans from Phyllanthus niruri L. in plasma using a simple HPLC method with fluorescence detection and its application in a pharmacokinetic study. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences — PubMed PMID: 17261384
5. Murugaiyah V, Chan KL (2009). Mechanisms of antihyperuricemic effect of Phyllanthus niruri and its lignan constituents. Journal of Ethnopharmacology — PubMed PMID: 19397979
6. Liu S, Wei W, Shi K, et al. (2014). In vitro and in vivo anti-hepatitis B virus activities of the lignan niranthin isolated from Phyllanthus niruri L. Journal of Ethnopharmacology — PubMed PMID: 25009077
7. Ito H (2011). Metabolites of the ellagitannin geraniin and their antioxidant activities. Planta Medica — PubMed PMID: 21294073
8. Yuan H, Zhang J, Yin X, et al. (2021). The protective role of corilagin on renal calcium oxalate crystal-induced oxidative stress, inflammatory response, and apoptosis via PPAR-γ and PI3K/Akt pathway in rats. Biotechnology and Applied Biochemistry — PubMed PMID: 33080078

PubMed Topic Searches

1. Phyllanthus pharmacokinetics — PubMed
2. Phyllanthin and CYP3A4 — PubMed
3. Geraniin bioavailability & urolithin — PubMed
4. Corilagin & calcium oxalate — PubMed
5. Niranthin and HBV — PubMed
6. Phyllanthus uricosuric mechanism — PubMed
7. P. urinaria ellagitannin chemotype — PubMed
8. Phyllanthin and P-glycoprotein — PubMed

Back to Table of Contents

Connections

• All Herbs
• Chanca Piedra Overview
• Phyllanthus Species Comparison
• Kidney Stone Protocol
• Liver Protection and Hepatitis B
• Blood Sugar and Metabolic Effects
• Uric Acid, Gout and Hypertension
• Forms, Dosing and Standardization
• Safety and Drug Interactions
• Quercetin
• Oxidative Stress
• Kidney Stones
• Hepatitis B
• Milk Thistle
• Uric Acid
• Calcium
• History Traditional Use and Botany

Back to Table of Contents

×

Featured Videos